Please be advised that this information was generated on 2018-05-11 and may be subject to change.T h e ne w e ngl a nd jou r na l o f m e dic i ne n engl j med 355;7 www.nejm

There is a higher prevalence of vertebral deformities and clinical manifestations of vertebral fractures in patients on Cs than in those not on Cs. Our data indicate that the use of Cs and each 1-mg increase in the current daily Cs dose may increase the risk of development of a vertebral deformity and symptomatic vertebral fracture in patients with RA.

No abstract

Please be advised that this information was generated on 2019-04-05 and may be subject to change.T h e ne w e ngl a nd jou r na l o f m e dic i ne n engl j med 355;7 www.nejm